| 8.71 -0.08 (-0.91%) | 09-11 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | ||||
| Targets | 6-month : | 11.85 | 1-year : | 13.84 |
| Resists | First : | 10.14 | Second : | 11.85 |
| Pivot price | 9.35 |
|||
| Supports | First : | 7.33 |
Second : | 5.59 |
| MAs | MA(5) : | 9.03 |
MA(20) : | 9.13 |
| MA(100) : | 6.64 |
MA(250) : | 6.94 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 12.2 |
D(3) : | 29.5 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 11.57 | Low : | 4.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SENS ] has closed above bottom band by 6.2%. Bollinger Bands are 31.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.98 - 9.03 | 9.03 - 9.07 |
| Low: | 8.42 - 8.49 | 8.49 - 8.54 |
| Close: | 8.61 - 8.71 | 8.71 - 8.8 |
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Thu, 10 Sep 2026
A glucose monitor can measure levels for up to 365 days. Senseonics plans two conferences. - Stock Titan
Mon, 24 Aug 2026
Douglas Roeder Bought 9.5% More Shares In Senseonics Holdings - simplywall.st
Thu, 20 Aug 2026
Senseonics Holdings (SENS) director boosts stake to 171,191 shares - Stock Titan
Sat, 08 Aug 2026
Senseonics (SENS) Stock Price Jumps On Growth While Losses Deepen - simplywall.st
Thu, 06 Aug 2026
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Fri, 31 Jul 2026
Senseonics Holdings, Inc. Revenue Breakdown – NASDAQ:SENS - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |